Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 7/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3390610 | 0.84 | CNR2 (0.56) | CHRNA7HTR3ACHRNB4CHRNA3CNR2 | |
| SCHEMBL3389708 | 0.84 | CHRNA7 (0.45) | CHRNA7HTR3ACHRNB4CHRNA3CNR2 | |
| SCHEMBL3391068 | 0.82 | CNR2 (0.60) | CHRNA7HTR3ACHRNB4CHRNA3CNR2 | |
| SCHEMBL928191 | 0.81 | CHRNA7 (0.68) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL2678055 | 0.80 | IL4I1 (0.46) | CHRNA7HTR3ACHRNB4CHRNA3CNR2 | |
| SCHEMBL2677508 | 0.78 | CNR2 (0.58) | CHRNA7HTR3ACHRNB4CHRNA3CNR2 | |
| SCHEMBL3390644 | 0.77 | MAOA (0.40) | CHRNA7HTR3ACHRNB4CHRNA3CNR2 | |
| SCHEMBL3391568 | 0.77 | CHRNA7 (0.49) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL1449402 | 0.76 | CHRNA7 (0.64) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL2676639 | 0.76 | CHRNA7 (0.64) | CHRNA7HTR3ACHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805183-B1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH AS (DK) | 2010-12-29 | — | — | EP | claimed |
| US-20080153806-A1 | Novel Diazabicyclic Aryl Derivatives And Their Medical Use | NEUROSEARCH A/S (DK) | 2008-06-26 | — | — | US | claimed |
| EP-1805183-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2007-07-11 | — | — | EP | claimed |
| WO-2006045716-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2006-05-04 | — | — | WO | claimed |
| EP-1805183-B1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH AS (DK) | 2010-12-29 | — | — | EP | disclosed |
| US-20080153806-A1 | Novel Diazabicyclic Aryl Derivatives And Their Medical Use | NEUROSEARCH A/S (DK) | 2008-06-26 | — | — | US | disclosed |
| EP-1805183-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006045716-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153806-A1 | Novel Diazabicyclic Aryl Derivatives And Their Medical Use | CHRNA6, CHRNA10, CHRNA2 | CHRNA7 6/4885HTR3A 117/4885CHRNB4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.